Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + cadonilimab
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + cadonilimab is a combination therapy consisting of two agents with distinct mechanisms of action. Anlotinib is a small molecule multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. Cadonilimab is a bispecific monoclonal antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This combination has been investigated in clinical trials for advanced non-small cell lung cancer (NSCLC), pulmonary large cell neuroendocrine carcinoma (LCNEC), cervical cancer, and esophageal squamous cell carcinoma, particularly in patients who are resistant to prior immunotherapy or chemotherapy. The regimen aims to provide synergistic anti-tumor effects by combining antiangiogenic therapy with dual checkpoint blockade[1][2][3][4][5][7].
- Brand names
- Fucaso
- Other names
- anlotinib plus cadonilimabcadonilimab and anlotinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + cadonilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + cadonilimab.